Natalizumab for Achieving Relapse-Free, T1 Gadolinium-Enhancing-Lesion-Free, and T2 Lesion-Free Status in Japanese Multiple Sclerosis Patients: A Phase 2 Trial Subanalysis

por Saida, Takahiko, Kira, Jun-Ichi, Kishida, Shuji, Yamamura, Takashi, Ohtsuka, Nobuhisa, Dong, Qunming, Tibung, J. T.
Publicado 2017

Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial

por Saida, Takahiko, Kira, Jun-Ichi, Kishida, Shuji, Yamamura, Takashi, Ohtsuka, Nobuhisa, Ling, Yan, Torii, Shinichi, Lucas, Nisha, Kuesters, Geoffrey, Steiner, Deb, Tibung, J. T.
Publicado 2016